Shares of Ventyx Biosciences, Inc. (VTYX) tumbled 5.47% in pre-market trading on Friday, despite several analysts raising their target prices for the stock. The sharp decline suggests that the company's third-quarter earnings report, released after market close on Thursday, may have fallen short of investor expectations.

Ventyx Biosciences announced its Q3 2025 financial results late Thursday, but the market's negative reaction indicates that the report might have contained disappointing news or guidance. This comes as a surprise, given that multiple financial institutions, including Jefferies, Canaccord Genuity, and Wells Fargo, all raised their target prices for VTYX following the earnings release.

The contrasting signals between analyst optimism and the stock's performance highlight the complexity of the situation. Jefferies increased its target price to $14 from $12, Canaccord Genuity raised its target to $16 from $14, and Wells Fargo upped its target to $14 from $11. Despite these positive adjustments, investors appear to be focusing on potential negative aspects of the earnings report, leading to the significant pre-market sell-off. As the trading day progresses, it will be crucial to monitor any further developments or analyst commentary that might shed light on the reasons behind this unexpected stock movement.